Literature DB >> 18289198

Laparoscopic antireflux surgery: key to success in the community setting.

Joel E Richter, Daniel T Dempsey.   

Abstract

Studies from large volume centers of excellence have proven the efficacy of laparoscopic antireflux surgery. However, the majority of these operations are performed in community hospitals, where the results are more variable. Major issues potentially affecting laparoscopic antireflux surgery in community hospitals include a) the individual skills and experience of the surgeons, b) the volume of operations per surgeon and hospital, and c) the sophistication of the esophageal motility labs evaluating these patients prior to surgery. Another evolving issue is the increasing number of fundoplication failures and where best to evaluate and treat these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18289198     DOI: 10.1111/j.1572-0241.2007.01602.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

Review 1.  Magnetic sphincter augmentation for gastroesophageal reflux disease: review of clinical studies.

Authors:  Emanuele Asti; Alberto Aiolfi; Veronica Lazzari; Andrea Sironi; Matteo Porta; Luigi Bonavina
Journal:  Updates Surg       Date:  2018-07-18

2.  SAGES technology and value assessment committee (TAVAC) safety and effectiveness analysis: LINX® reflux management system.

Authors:  Dana A Telem; Andrew S Wright; Paresh C Shah; Matthew M Hutter
Journal:  Surg Endosc       Date:  2017-08-25       Impact factor: 4.584

3.  20 years later: laparoscopic fundoplication durability.

Authors:  Ben Robinson; Christy M Dunst; Maria A Cassera; Kevin M Reavis; Ahmed Sharata; Lee L Swanstrom
Journal:  Surg Endosc       Date:  2014-12-09       Impact factor: 4.584

4.  LINX(®) Reflux Management System in chronic gastroesophageal reflux: a novel effective technology for restoring the natural barrier to reflux.

Authors:  Luigi Bonavina; Greta Saino; John C Lipham; Tom R Demeester
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.